Life Insurance for Behcet’s Disease
Life Insurance for Behcet’s Disease
Jason Stolz CLTC, CRPC
Life insurance for Behcet’s disease is absolutely possible — but approvals and pricing depend on how active the condition has been, which organ systems are involved, and how well symptoms are controlled over time. Behcet’s syndrome is an inflammatory condition that can cause flare-ups affecting the mouth, skin, eyes, joints, blood vessels, and in more serious cases the nervous system or gastrointestinal tract. From an underwriting perspective, carriers focus less on the diagnosis label and more on the severity, complications, current stability, treatment history, and quality of recent specialist follow-up that the medical record demonstrates.
At Diversified Insurance Brokers, we help clients with complex medical histories compare carrier underwriting approaches so they do not waste time applying to the wrong company. Behcet’s is a condition where one carrier may offer a reasonable outcome when another declines — especially when your case is stable, well-managed, and free of high-risk organ complications. On this page, we walk through what insurers evaluate, what documentation helps most, what severity means for approval and pricing, and what to do if you have been declined before.
Get a Behcet’s Life Insurance Quote
We match your case to carriers that regularly consider autoimmune and inflammatory conditions — so you can see realistic options without guessing.
Can You Get Life Insurance With Behcet’s Disease?
Yes — many people with Behcet’s qualify for life insurance, including traditional term and permanent policies. Carriers generally want to see that the condition is diagnosed, followed by a specialist, and stable with a clear and documented treatment plan. Underwriting outcomes are most favorable when there is limited organ involvement and few or no serious complications over the medical history.
Behcet’s is typically reviewed in a similar framework to other inflammatory and autoimmune diagnoses — meaning the carrier is assessing your flare pattern, complication risk, and overall health stability rather than reacting to the diagnosis name alone. If you are exploring how underwriting approaches complex medical histories more broadly, our resource on life insurance with pre-existing conditions provides a useful foundation for understanding how carriers evaluate applicants with ongoing health conditions.
What matters most in Behcet’s underwriting is whether the condition has remained primarily mucocutaneous — meaning mouth ulcers, skin lesions, and joint involvement — versus progressing into higher-risk organ involvement such as ocular disease, vascular clotting, neurologic events, or recurrent gastrointestinal complications. Underwriters also pay close attention to stability over time. An applicant who has had a stable pattern with predictable management and no recent escalation looks very different in underwriting than an applicant with a recent spike in disease activity, new organ involvement, or frequent high-dose steroid requirements. It also helps to understand that underwriting is not purely about the Behcet’s diagnosis. Two applicants with identical Behcet’s histories can receive meaningfully different offers depending on blood pressure, weight, tobacco history, driving record, and other comorbidities. Behcet’s may be the headline, but the final offer is shaped by the complete file.
What Underwriters Look At for Behcet’s Disease
Insurance underwriters evaluate Behcet’s using practical risk questions about how much of the body is involved, how often flares occur, whether serious complications have developed, and whether medical records show consistent specialist care with documented stability. The answers to these questions — supported by actual documentation — drive the underwriting outcome more than any general statement about the condition.
Organ involvement and complications are the most heavily weighted factor. Behcet’s can range from primarily mucocutaneous symptoms to serious involvement of the eyes, blood vessels, nervous system, and gastrointestinal tract. Carriers pay particular attention to eye involvement including uveitis and retinal vasculitis with any associated vision loss; vascular Behcet’s including blood clots, aneurysms, and vasculitis; neurologic Behcet’s including stroke-like events, CNS inflammation, and seizures; and significant GI involvement including intestinal ulcers, bleeding, and hospitalizations. When ocular, vascular, neurologic, or significant gastrointestinal involvement appears in the history, underwriters typically shift their assessment from “manageable inflammatory condition” to “potentially elevated mortality exposure,” which narrows carrier appetite and changes how aggressively pricing is applied. That is precisely where carrier selection and timing of application matter most. For comparison context on how other inflammatory and autoimmune conditions are evaluated, our resources on life insurance for rheumatoid arthritis and life insurance for colitis and Crohn’s disease provide useful parallel frameworks.
Frequency and severity of flare-ups is the second major factor. Underwriters look for patterns across the history — how often flares occur, how severe they are, whether they have required ER care, hospitalization, or high-dose steroid intervention. They also look for trend direction. A history showing improvement over time underwrites better than one showing escalating activity or increasing treatment intensity. Carriers generally view long stretches of stability as favorable even when occasional mild flares are documented. The underwriting question becomes whether flares are mild and predictable with quick resolution, or whether they lead to major interventions and complications that signal ongoing systemic vulnerability.
Treatment plan quality and specialist follow-up continuity are the third critical dimension. Carriers prefer to see consistent care with a rheumatologist and with any involved specialty — ophthalmology, hematology, neurology, or gastroenterology as applicable. A stable medication plan with documented response and clear specialist notes describing symptoms as controlled carries substantial positive weight. Gaps in specialist care, incomplete records, or unclear treatment rationale can slow underwriting or produce conservative outcomes even when the underlying disease course is stable. Underwriters look for evidence that the current management plan is working — fewer severe flares, fewer emergency visits, fewer steroid bursts, and stable specialist notes over time.
Comorbidities and overall health profile form the fourth dimension that shapes the final rate class. Blood pressure, cholesterol, body weight, tobacco use, sleep apnea, and other medical conditions can materially change the offer even when Behcet’s itself is well-controlled. This is one of the primary reasons applicants with Behcet’s receive meaningfully different offers from different carriers — both the carrier’s appetite for the Behcet’s profile specifically and its tolerance for cumulative risk from the overall file influence where the offer lands.
How Severity Affects Approval and Rates
Behcet’s disease exists across a wide severity spectrum, and that spectrum maps directly onto underwriting outcomes. Understanding where your case falls — and how to document it clearly — is essential for maximizing both approval probability and rate competitiveness.
For applicants whose Behcet’s has primarily involved recurring oral ulcers, skin lesions, and occasional joint pain with no eye, vascular, neurologic, or significant gastrointestinal involvement, many carriers will consider standard or near-standard underwriting. Stable management, minimal steroid use, strong follow-up documentation, and a favorable overall health profile can position this category of applicant for meaningful term life insurance coverage. The key underwriting theme for this group is “controlled inflammatory disease with limited systemic risk,” and the pool of viable carrier options is wider than for more complex presentations.
For applicants with moderate disease that requires intermittent steroids, immunosuppressants, or more frequent specialist care, carriers often offer coverage with a rating — a premium surcharge above standard that reflects the additional mortality exposure. The specific outcome depends heavily on whether serious complications have developed and whether stability is improving over time. Underwriters focus on the frequency of significant flares, how recently higher-intensity treatment was needed, and whether any organ involvement has occurred. This category is often where the independence of the broker matters most — one carrier may apply a heavier rating while another prices the case more competitively when stability is clearly documented. For applicants in a similar moderate-disease category with a different underlying condition, our resource on life insurance for atrial fibrillation illustrates how carriers evaluate conditions that are manageable but carry elevated risk without careful presentation.
For applicants with higher-risk Behcet’s involving ocular disease, vascular complications, neurologic episodes, or recurrent hospitalizations, heavier ratings, postponements, or declines are possible depending on the recency and severity of those events. In these situations, carrier selection becomes the dominant factor because underwriting appetite varies dramatically across the market. When the file shows serious historical involvement but also demonstrates strong long-term stability since those events, some carriers may still consider coverage — often with modified pricing or specific exclusions. Our resources on best high-risk life insurance companies and life insurance for stroke provide relevant context for applicants in this category, given the overlap between stroke-related neurologic events and the neurologic manifestations that can appear in complex Behcet’s cases.
Life Insurance Quoter
Want to see baseline term life pricing first? Compare options instantly here, then we’ll tailor the best carrier choice to your Parkinson’s history.
Records and Labs That Help Most
The goal in preparing a Behcet’s life insurance file is not to prove perfection — it is to demonstrate clarity and documented stability. Underwriters make decisions based on what the medical record actually says, so the strongest Behcet’s submissions provide recent specialty notes, a clear disease timeline, and supporting records that confirm the scope of involvement and the quality of the management response.
Specialist notes from the rheumatologist — and from any involved specialty such as ophthalmology, hematology, neurology, or gastroenterology — form the backbone of a strong submission. These notes should ideally reflect a consistent care relationship with documented assessment of disease activity, treatment response, and current stability. A clear timeline of flares — including frequency, severity, treatment used, and resolution — gives underwriters a structured view of how the disease has behaved over time and whether the trajectory is improving. The current medication list with start dates and any recent changes provides the treatment context that makes the clinical picture coherent. Ophthalmology records are especially important if there has been any eye involvement, even historical, because ocular Behcet’s carries specific mortality and morbidity implications that underwriters evaluate separately from mucocutaneous disease. Imaging studies, vascular workups, and any prior clot or vasculitis evaluation should be included if those evaluations occurred, because their absence from the file can create questions about whether vascular involvement is actually present but unaddressed. Recent labs that reflect inflammatory control — including inflammatory markers, organ function panels where applicable, and any specialty-specific labs — round out the picture of current disease status.
Underwriters care most about the presence or absence of the specific complications that change mortality exposure: vascular events, neurologic episodes, vision-threatening ocular disease, and recurrent hospital-level GI complications. When records clearly document that those complications are not present, or have not recurred in a meaningful period of stability, the underwriting picture becomes considerably more predictable. If you are uncertain how carriers use medical records in the underwriting decision, our resource on what is a life insurance exam explains how the review process works and what documentation is requested at different coverage levels.
How Medications Affect Underwriting for Behcet’s
Medication use does not automatically hurt underwriting outcomes — what matters is why the medication is needed, how stable the condition is on the current regimen, and whether the treatment reflects aggressive management of a condition that is responding well or escalating management of a condition that is not. Carriers commonly see colchicine, intermittent corticosteroids, immunosuppressants such as azathioprine or methotrexate, and biologic agents in Behcet’s files depending on the disease pattern and severity.
In underwriting logic, stronger therapy can signal more severe disease — but it can also demonstrate that the condition is being aggressively and successfully controlled, which actually supports the stability argument when the clinical record confirms that approach is working. Underwriters respond better to “active treatment with documented stable control” than to “infrequent care with unclear stability,” because the former shows the disease is being managed while the latter leaves the true disease activity ambiguous. What most concerns underwriters in a Behcet’s medication review is trajectory. Have medications escalated recently, or has the applicant been stable on a consistent regimen for a meaningful period? Stability on a well-tolerated regimen for 12 to 24 months or longer is viewed positively. Frequent medication changes, repeated high-dose steroid bursts, or recent additions of new medications for new manifestations raise concern because they suggest disease activity that is not yet contained.
Term vs Permanent Life Insurance for Behcet’s
Term life insurance is generally the first coverage structure to evaluate for applicants with Behcet’s who want maximum coverage at the lowest premium. If you qualify at an acceptable rate class, term can be a practical and cost-effective way to lock in protection for a defined period — 10, 15, 20, or 30 years — especially during the years when income replacement and debt protection carry the highest stakes for your household. Our resources on 20-year term life insurance and 30-year term life insurance cover how term length selection interacts with different household planning timelines.
Permanent life insurance — whole life or universal life — may be more appropriate when you want lifelong coverage, estate planning utility, or prefer to secure coverage while your condition is currently stable rather than risk applying later under potentially different health conditions. For applicants with Behcet’s who anticipate that future health developments could make coverage harder to obtain or more expensive, permanent coverage secured at a favorable underwriting moment preserves long-term access in a way that term does not. Some applicants also consider permanent options when they want the conversion safety net — the ability to convert a term policy to permanent coverage without new medical underwriting — as a backstop for future planning flexibility. Our resource on converting term to permanent life insurance explains how that option works and when it is most valuable. For applicants managing Behcet’s alongside other complex health conditions that affect underwriting, our parallel guides on life insurance for pulmonary diseases, life insurance for anemia, and life insurance for elevated liver enzymes illustrate how multiple risk factors interact within a single file.
If You Have Been Declined Before
A prior decline does not mean you are uninsurable — it frequently means the application went to a carrier whose underwriting appetite did not match your specific profile, or the file lacked the documentation detail needed for the carrier to make a confident approval decision. Common triggers for declines on Behcet’s applications include recent severe flares, unclear organ involvement documentation, missing specialty follow-up records, a file that did not adequately establish the current stability of the condition, or an application submitted to a carrier whose general approach to autoimmune inflammatory conditions is conservative regardless of individual disease management.
If you have been declined, the most productive next step is identifying what triggered the decision, ensuring the documentation gap or timing issue is addressed, and approaching carriers with a better underwriting fit for your specific profile. Timing matters in this process. If your disease has become demonstrably more stable since the decline, if records now clearly document limited organ involvement, or if a meaningful period of stability has elapsed since the events that drove the decline, options that were not available at the prior application date may now be accessible. Our resource on what to do if you are denied life insurance provides a practical framework for working through the next steps after a decline. For applicants who want to understand how table ratings work when standard approval is not available, our resource on life insurance table ratings explained covers what table ratings are, how they affect premiums, and what they mean for long-term coverage planning.
How to Improve Your Chances of Approval and Competitive Rates
Several practical steps improve both the probability of approval and the competitiveness of the rate offered for life insurance applicants with Behcet’s disease. Demonstrating documented stability over time is the single most important factor — carriers respond to clear evidence that the disease course has been stable and the management plan is working. Maintaining regular specialist follow-up so that the record reflects current, consistent, and documented care creates the foundation that underwriters need to make a confident decision. Keeping records of flares and treatment responses — even informally, as a supplement to specialist notes — helps when submitting a file that tells a coherent story of how the disease has behaved and improved.
Addressing other controllable risk factors before applying — tobacco cessation, blood pressure management, weight — can move the overall file from a borderline category to a more favorable one, because underwriters price the complete profile rather than the Behcet’s diagnosis alone. Applying through an independent broker who knows which carriers approach autoimmune and inflammatory conditions most favorably for your specific severity pattern — rather than applying broadly or blindly — prevents unnecessary application records and focuses effort on the carriers most likely to produce a workable outcome. For applicants who are also managing disability income protection needs alongside life insurance planning, our resource on high-risk disability insurance for those with medical challenges covers the parallel underwriting considerations for disability income coverage when a complex health history is involved.
Related High-Risk Life Insurance Resources
Compare Term Life Insurance Lengths
Explore different term periods to find coverage that best matches your timeline and budget.
Talk With an Advisor Today
Choose how you’d like to connect—call or message us, then book a time that works for you.
Schedule here:
calendly.com/jason-dibcompanies/diversified-quotes
Licensed in all 50 states • Fiduciary, family-owned since 1980
Life Insurance for Behcet’s Disease FAQs
Yes — many applicants with Behcet’s disease qualify for term life insurance, including coverage at standard or near-standard rate classes when the condition is well-managed. The key factors that determine term life eligibility are whether symptoms are stable over a documented period, whether specialist follow-up is consistent and current, and whether the medical history shows limited organ involvement — specifically no serious ocular, vascular, neurologic, or significant gastrointestinal complications. Applicants whose Behcet’s has primarily involved mucocutaneous symptoms and occasional joint flares, managed with a consistent treatment plan and regular rheumatology follow-up, often find that term life insurance is accessible at workable pricing. Applicants with moderate disease — including periodic flares requiring intermittent steroids or immunosuppressants — may qualify with a rated premium that is higher than standard but still provides meaningful protection. The most important practical step is working with an independent broker who knows which carriers approach autoimmune inflammatory conditions favorably for your specific disease pattern, because carrier appetite for Behcet’s varies considerably across the market and applying to the wrong carrier can produce an unnecessary decline that affects future applications.
Carriers focus primarily on the potential for organ-level complications when evaluating Behcet’s disease, because those complications represent the most significant sources of elevated mortality exposure. The highest-concern categories are ocular Behcet’s — particularly uveitis and retinal vasculitis with associated vision loss — because it signals a more systemic and aggressive inflammatory process than mucocutaneous disease alone. Vascular Behcet’s involving blood clots, aneurysms, or significant vasculitis raises substantial concern because of the cardiovascular and thromboembolic mortality implications. Neurologic Behcet’s involving stroke-like events, CNS inflammation, or seizures creates significant underwriting concern because of both the severity of the events and the unpredictability of recurrence. Severe gastrointestinal involvement requiring hospitalization represents another elevated risk category. Frequent flare-ups requiring high-dose steroids, repeated hospitalizations, and rapidly escalating treatment are also viewed negatively because they signal disease that is not yet well controlled. Applicants who have avoided these complications and demonstrate stable, limited disease with consistent management typically represent a much more manageable underwriting risk than the diagnosis label alone might suggest.
No — medication use is evaluated in context rather than as an automatic negative signal. Underwriters assess what the medication indicates about disease severity and trajectory, not simply whether a medication is present in the file. For Behcet’s, medications commonly seen include colchicine, intermittent corticosteroids, immunosuppressants such as azathioprine or methotrexate, and in some cases biologic agents. A patient on a consistent immunosuppressant regimen with documented stable disease and infrequent flares may underwrite more favorably than a patient on minimal medication but with an unstable or unclear disease course. The underwriting question is: does the current medication plan reflect aggressive management of a condition that is responding well, or does it reflect escalating effort to control a condition that is not yet stable? Stability on a consistent regimen for a meaningful period — typically 12 months or longer without significant changes, new organ involvement, or repeated high-dose steroid bursts — carries positive weight. Frequent medication changes, recent addition of new medications for new manifestations, or repeated corticosteroid courses for uncontrolled flares raise concerns because they indicate ongoing disease activity that the current plan has not contained.
The strongest Behcet’s submissions provide documentation that clearly establishes the scope of disease involvement, the stability of the disease course, and the quality of ongoing specialist management. Rheumatology notes form the backbone — ideally reflecting consistent visits over a meaningful period with documented assessment of disease activity, treatment response, and current stability. Notes from any involved specialty are equally important: ophthalmology records if there has been any ocular involvement, hematology or vascular records if clotting or vasculitis was evaluated, neurology records if any neurologic events or concerns occurred, and gastroenterology records if GI involvement was present. The medication list with start dates and any recent changes provides the treatment context that makes the clinical picture coherent. A clear timeline of flares — frequency, severity, treatment required, and resolution — gives underwriters a structured view of how the disease has behaved. Recent labs reflecting inflammatory control and organ function, where applicable, support the current stability argument. Underwriters focus most on documentation that addresses the specific complications they find most concerning: vascular events, neurologic episodes, vision-threatening ocular disease, and hospital-level GI complications. When records clearly document the absence of those complications or their stability over a meaningful period, the underwriting outcome becomes considerably more predictable and favorable.
Whether a paramedical exam is required depends on the coverage amount, the applicant’s age, and the specific carrier’s underwriting requirements. Many life insurance policies — particularly at lower coverage amounts for younger applicants — offer accelerated underwriting that relies on electronic data sources, application information, and medical records rather than a traditional in-person exam. At higher coverage amounts or older ages, carriers typically require a paramedical exam that includes height and weight measurements, blood pressure, pulse, and blood and urine sample collection. For applicants with Behcet’s, the exam itself is not the primary underwriting concern — it is the medical records and specialist documentation that drive the decision. Lab results from the paramedical exam may be used to evaluate inflammatory markers, organ function, and other health indicators, but the underwriter’s central questions about Behcet’s severity, complications, and stability will be answered by the specialist records rather than the standard exam labs. Some carriers use the exam as an opportunity to request attending physician statements, particularly for complex medical histories, which can add time to the underwriting process. Working with a broker who can prepare a well-documented file that addresses underwriter questions proactively tends to reduce underwriting delays and produces better outcomes than relying solely on the exam to tell the story.
A prior decline is not a permanent conclusion about your insurability — it is most commonly a signal that the application went to a carrier whose underwriting appetite did not match your specific profile, or that the file at the time of application did not provide sufficient documentation for the carrier to make a confident approval decision. Common reasons for Behcet’s-related declines include recent severe flares or hospitalization that was too close in time to the application, unclear or incomplete documentation of organ involvement and specialist follow-up, missing records that left underwriters uncertain about actual disease scope, or an application submitted to a carrier that takes a conservative approach to all autoimmune and inflammatory conditions regardless of individual clinical stability. The productive response to a decline is to identify the specific reason — which your broker can often determine by requesting feedback from the carrier — tighten the documentation to address the identified gap, allow appropriate time if timing was the issue, and approach carriers with better underwriting fit for your specific profile. If your disease has become more demonstrably stable since the decline, or if records now clearly document limited organ involvement that was ambiguous before, your options may be materially different from those available at the time of the prior application.
Not necessarily — underwriting standards for permanent life insurance are generally similar to those for term, and many carriers apply the same rate class determination to both product types for medically complex applicants. The choice between term and permanent coverage for someone with Behcet’s is driven more by planning goals and budget than by underwriting accessibility. If term pricing is workable and your primary protection need is time-bound — covering income replacement years, a mortgage payoff timeline, or a period while children are dependent — term is typically the more cost-efficient solution and allows the largest face amount for the available budget. Permanent coverage becomes more appropriate when the protection need is lifelong, when estate planning is a consideration, or when there is genuine concern that future health developments might make obtaining additional coverage more difficult. In that last scenario, locking in permanent coverage while the Behcet’s is in a stable phase can be a strategic decision — it guarantees a lifelong death benefit regardless of what happens to underwriting eligibility in future years. The conversion option available on many term policies provides a middle path: purchase term at the current stable underwriting moment, with the contractual right to convert to permanent coverage later without new medical underwriting, even if health changes in the interim.
Several practical steps meaningfully improve both approval probability and rate competitiveness for life insurance applicants with Behcet’s. Demonstrating documented stability over the longest possible period is the most impactful single factor — the longer the documented stable interval since any significant flare, complication, or treatment escalation, the more favorably underwriters view the case. Maintaining consistent specialist follow-up — rheumatology at minimum, with any involved specialties as applicable — ensures that the medical record reflects current, active, and documented disease management rather than gaps that raise underwriter uncertainty. Keeping records of flares and treatment responses between official specialist visits, to supplement those notes, creates a more complete documentary record of how the disease has behaved over time. Addressing controllable comorbidities before application — tobacco cessation, blood pressure management, weight management — can shift the overall file from a borderline category to a more favorable one, because underwriters price the complete health profile and Behcet’s is often not the only risk factor present. Finally, working with an independent broker who can identify which specific carriers have the most favorable underwriting positions for your specific Behcet’s severity pattern and overall health profile prevents wasted applications and focuses effort where meaningful approval is most likely to occur.
Yes — Behcet’s disease is evaluated in disability income insurance underwriting with similar principles to life insurance, but the specific risk factors carry somewhat different weight because disability insurance is assessing the probability of inability to work rather than mortality risk. For disability insurance underwriting, carriers focus on the likelihood that Behcet’s would result in work absence due to flares, complications, or ongoing functional limitations — including vision problems from ocular involvement, neurologic symptoms that affect cognitive or physical capacity, or severe fatigue and pain during active disease periods. Mucocutaneous Behcet’s with limited functional impact is generally viewed more favorably for disability underwriting than presentations involving eye disease, neurologic symptoms, or vascular complications that could directly affect work capacity. The same documentation principles apply: specialist records, flare frequency and severity documentation, medication stability, and specialist follow-up all shape the outcome. Some carriers may offer disability coverage with an exclusion rider that excludes claims related to Behcet’s while covering other causes of disability, which may be more accessible than a fully rated policy for applicants with more complex disease patterns. Working with an independent broker who can compare which disability carriers are most accommodating for autoimmune and inflammatory conditions — and who understand the distinction between life and disability underwriting approaches — produces the best outcome for applicants managing both protection needs simultaneously.
An independent broker represents access to the full competitive marketplace — comparing underwriting standards, carrier appetites, rate class criteria, and product structures across more than 100 carriers — rather than being limited to a single company’s approach. For Behcet’s disease specifically, this market access is particularly valuable because carrier underwriting appetites for autoimmune and inflammatory conditions vary considerably. A carrier that takes a conservative approach to all inflammatory conditions may decline or heavily rate an application that another carrier would approve at a standard or moderately rated class, based on identical medical facts. The difference between those outcomes is carrier selection — and carrier selection is only possible when the broker has access to multiple carriers and understands how each one approaches the specific risk profile being presented. An independent broker can also prepare the file strategically — ensuring the documentation that addresses underwriter concerns is organized clearly and that the submission tells the most complete and accurate story of the applicant’s stability and management. For a condition like Behcet’s where the underwriting narrative matters as much as the diagnosis, the quality of the file presentation meaningfully affects the outcome. At Diversified Insurance Brokers, we have worked with clients managing complex autoimmune and inflammatory conditions since 1980, and our approach begins with understanding the full medical picture before identifying which carriers are most likely to view that picture favorably.
About the Author:
Jason Stolz, CLTC, CRPC, DIA, CAA and Chief Underwriter at Diversified Insurance Brokers (NPN 20471358), is a senior insurance and retirement professional with more than two decades of real-world experience helping individuals, families, and business owners protect their income, assets, and long-term financial stability. As a long-time partner of the nationally licensed independent agency Diversified Insurance Brokers, Jason provides trusted guidance across multiple specialties—including fixed and indexed annuities, long-term care planning, personal and business disability insurance, life insurance solutions, Group Health, and short-term health coverage. Diversified Insurance Brokers maintains active contracts with over 100 highly rated insurance carriers, ensuring clients have access to a broad and competitive marketplace.
His practical, education-first approach has earned recognition in publications such as VoyageATL, highlighting his commitment to financial clarity and client-focused planning. Drawing on deep product knowledge and years of hands-on field experience, Jason helps clients evaluate carriers, compare strategies, and build retirement and protection plans that are both secure and cost-efficient. Visitors who want to explore current annuity rates and compare options across multiple insurers can also use this annuity quote and comparison tool.
Explore More Life Insurance Options: Browse our complete guide to High Risk Life Insurance — covering health conditions, guaranteed issue, special needs & underwriting challenges from 100+ carriers.
